CD8A and neoplasm: RT exerts its anti-tumour efficacy by inducing direct damage to cancer cells, such as double-strand DNA breaks, but also through modification of the tumour microenvironment (TME) by inducing a local and systemic immune response [[3], [4], [5]], notably by activating CD8+ T cells [6].